Medical News Today -
11 Oct 2013 12:00
Promising results from a phase II trial published in the journal Gastroenterology suggest adding the new drug danoprevir to the current standard care (peginterferon and ribavirin) for patients with hepatitis C leads to high rates of remission. The results raise hopes that Roche's new drug can improve the quality of life for patients with hepatitis C. Lead author Dr...
Share this Article